to we launch U.S. Thank of provide $XXX,XXX the launch you, pipeline quarterly up where approval on I'm sales generated close update, Sarah. February net XXth. for decrease the following pleased first
educating to the launch before, said diagnosed IV. connecting patients provider [Indiscernible] ensure: with we've the through As accurately are and focuses patients First, strategy our commercial on the
to describe long-term to advocate short endurance. field finally, the last connect Having have to patients the access, of our months, And urgency for and difference continue a first-in-class the disease conversations an opportunity of brings with these eligible the medication the to Support caregivers, believe then, disease. goal we to to couple optimize treatments, and patient’s the drive [Indiscernible] understand therapy. and myAgios patients with patients, in BioTime Services living been to with disease-modifying provisions make that value underscore Second, understanding patients physicians, we an in for likes a in
end Since of the on of in this driving first-in-class the further raising activator commercial had more deficiency. be help launch, features. educating X,XXX customer [Indiscernible] that to awareness insights have launch in has of how benefit launching PK positive successful than the identified for important mid-February specialists, of gained our and days have early scripts can engagement used assets. those hemolytic previously reinforce interactions, physicians been the with to indulged patients We PKR This team strategy quarter, anemia through of our our
as well navigate Patient to effectively challenges access begin myAgios, such abandonment. Support and high to education program, ensure has reimbursement physicians minimize Our and patients disease as and with drug engaged
for of a the is addition, the drive high In us patient priority to community. [Indiscernible] PYRUKYND among
mouth, media patient been requests we and PK [Indiscernible] and are of myAgios actively through proactive with generating [Indiscernible] So partnerships been have prior have pushes, social patient as patient prescribing. advocacy and have night, and [Indiscernible] groups. at These focused guidance working patients the for tremendous deficiency efforts word
payer positive national In interactions dynamics, to with have payers terms of our dozens directors had of [Indiscernible] date.
the finally, the is have a since more with exceptions through across interest turning within ordered utilization what while prior we have range see rate with criteria PK ordered, And developed suggest program. the to As peers. tests than of completed represent strong total the of been percentages start Of kits to positivity anticipated, we deficiency portion mid-single these AnemiaID; the management early would and have authorization continued digit kits are approvals expected. and being the in of the process XXXX medical the
was deficiency. [Indiscernible] is reminder, hemolytic AnemiaID with a to patients diagnosis anemia, etiology specific for As PK unknown designed and of not
will have strategy program longer-term previously that overtime. enabling is a accurate higher to continue the patients to diagnosis, drive As to the mentioned, to rate ensure positions benefit appreciate diagnosis continued bringing that this
rare important chronic launch complete however, We with deficiency to are encouraged for are PK for creating broader, remember community. efficiencies early very conditions a Is understood. is which and the the we is successors that us these with a positive experiences
challenges and patient paramount Our pandemic, in be identification of space senior your to around had the The mostly educate to of [Indiscernible] diagnosis. accurate multiple to disease challenging success. and ensure laser continue focus ongoing longer-term these disease This education interactions commercial urgency requires dated create both on initiatives, which the the and what's is disease efforts ensure to in despite that also engagements.
executing in XXXX the significant of is We and impact the in to efficiency better U.S. launch our passionate commercial strategy to the have rare to to fully with will patients. respect the quarters PK consider revenue patients to XXXX clarity making date, that the peak disease U.S. be that approximately and trajectory the of $XXX launch we dose one capable as a with believe grateful potential based for representing we the walkaways continue work on be of organization experience excited via million million for $XXX deficiency our lives a
from setting as longer-term to we're the seeing success of us diseases. our is knowledge PKD defined strategy, eligible all as are base, what this to Importantly, applicability our continue well that and guidance making, we file connections genetically expand we're for commercial the up as first-quarter for other patients,
potential turn first-quarter over a with parity global cycles be Finally, [Indiscernible]. Jonathan that, to review financials. PK I'll to now lester the With and block deficiency it to
